Trial Enrollment Watch — Week of July 14, 2026

New Registrations This Week

Our weekly scan identified forty-nine trials newly registered this week across therapeutic areas, led by rare disease (21) and oncology (15), with additional activity in immunology (5), cardiovascular (4), neurology (2), endocrinology (1), and respiratory (1). Site counts vary widely, from large multi-site Phase 3 programs to single-site or not-yet-listed designs.

NCT07686263 — Karuna Therapeutics (a Bristol Myers Squibb company), Schizophrenia, Phase 3, 61 sites
NCT07687186 — Tasly Pharmaceutical Group, Heart Failure, Phase 3, 60 sites
NCT07687459 — InSilico Medicine Hong Kong, Idiopathic Pulmonary Fibrosis, Phase 3, 47 sites
NCT07691970 — AstraZeneca, Systemic Sclerosis / Cutaneous Lupus / Myopathies / Systemic Lupus Erythematosus, Phase 3, 41 sites
NCT07692867 — Yangtze River Pharmaceutical Group, Erectile Dysfunction, Phase 3, 52 sites
NCT07686081 — Vanda Pharmaceuticals, Ulcerative Colitis, Phase 3, 2 sites
NCT07688772 — Guangdong Hengrui Pharmaceutical, Seasonal Allergic Rhinitis, Phase 3, 1 site
NCT07690371 — Nektar Therapeutics, Moderate-to-Severe Atopic Dermatitis, Phase 3, 1 site
NCT07691762 — Suzhou Suncadia Biopharmaceuticals, Hepatocellular Carcinoma, Phase 3, 1 site

Enrollment-Distress Flags

Our heuristics newly flagged five enrollment-distress indicators this week: three in rare disease, one in oncology, and one in immunology. Rare disease continues to be the therapeutic area most prone to enrollment friction, consistent with small eligible populations and geographically dispersed patients.

Overdue-Results Backlog: Scan Update

Our rolling index of the overdue-results backlog — trials completed more than 12 months ago with no results yet posted — added 359 trials this week as scan coverage expanded. This reflects our capped weekly scan progress against a large standing backlog (FDA's March 2026 initiative sized the full backlog at 3,000-plus trials), not new filings or a weekly trend.

By therapeutic area, oncology and rare disease account for the largest shares newly indexed this week, at 86 and 203 respectively. Neurology and endocrinology each added 16, cardiovascular 12, immunology 10, respiratory 9, and infectious disease 7.

Practical Takeaway

Sponsors planning site selection in rare disease and oncology should budget extra time for both enrollment ramp-up and results reporting compliance — these two areas dominate both the distress flags and the overdue-results backlog this week. Early identification of high-performing, compliance-ready sites can reduce downstream reporting risk.

Eichor AIOS generates free preliminary site-risk snapshots from public data for teams evaluating site selection or enrollment risk.

---

About these numbers. Individual trial facts — NCT IDs, sponsors, phases, site counts — come directly from ClinicalTrials.gov and can be verified there. Weekly totals, therapeutic-area breakdowns, enrollment-distress flags, and the overdue-results index are produced by Eichor's own daily registry scans and analysis heuristics; they are our measurements of public data, not statistics published by ClinicalTrials.gov or FDA. The 3,000-plus overdue-trials benchmark references FDA's March 2026 compliance reminders to 2,200-plus sponsors (FDA announcement). How we're built · How findings are signed.

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.